Brisbane, Australia and Delaware, United States, 19 May 2015: Australian respiratory technology company Invion Limited (ASX: IVX) is delighted to invite investors to listen to Invion’s Dr Mitchell Glass and Dr Mario Castro of Washington University discuss INV102 (oral nadolol) data that has been presented to international medical experts at a prestigious US pulmonary conference, the American Thoracic Society (ATS) Meeting.
In this audiocast, Drs Glass and Castro discuss:
- • Invion’s fully recruited phase 2 trial of INV102 (oral nadolol) in patients with chronic cough, and how can nadolol potentially help smokers to quit
- • Why this trial important for other respiratory diseases like asthma and COPD
- • Next steps for this clinical program
To access the audiocast, please visit this link: http://www.brrmedia.com/event/138657